Overview

Principal Investigator

Massimo Gadina, Ph.D.

Dr. Gadina is exploring immune-mediated diseases with a particular emphasis on the biology of cytokines, their relative signaling pathways and has an keen interest in the role of JAK inhibitors in the treatment of inflammatory and autoimmune diseases.

The development of accurate and reproducible immune monitoring assays is essential to determine the immune responses in patients receiving novel immune therapies and ultimately transitioning these therapies from the clinical trial phase to standard of care. The goal of the Translational Immunology Section (TIS) is to develop cutting edge immune monitoring technology that will be made available to all NIAMS investigators.

Services

The Translational Immunology Section provides NIAMS scientists with:

  • Services, consultative advice and in-depth instructions in a variety of immunologic methods to facilitate their interpretation of immunoassays most relevant to a particular clinical trial or to study a particular patient.
  • State-of-the-art immunoassays such as multicolor flow cytometry and Luminex, enabling NIAMS clinicians to monitor the immune responses of their clinical trial patients.
  • Analysis of a reference population to define baseline responses, ensuring quality control checks that will validate the reproducibility of these results.

Scientific Publications

 

 

Early-onset stroke and vasculopathy associated with mutations in ADA2.

Zhou Q, Yang D, Ombrello AK, Zavialov AV, Toro C, Zavialov AV, Stone DL, Chae JJ, Rosenzweig SD, Bishop K, Barron KS, Kuehn HS, Hoffmann P, Negro A, Tsai WL, Cowen EW, Pei W, Milner JD, Silvin C, Heller T, Chin DT, Patronas NJ, Barber JS, Lee CC, Wood GM, Ling A, Kelly SJ, Kleiner DE, Mullikin JC, Ganson NJ, Kong HH, Hambleton S, Candotti F, Quezado MM, Calvo KR, Alao H, Barham BK, Jones A, Meschia JF, Worrall BB, Kasner SE, Rich SS, Goldbach-Mansky R, Abinun M, Chalom E, Gotte AC, Punaro M, Pascual V, Verbsky JW, Torgerson TR, Singer NG, Gershon TR, Ozen S, Karadag O, Fleisher TA, Remmers EF, Burgess SM, Moir SL, Gadina M, Sood R, Hershfield MS, Boehm M, Kastner DL, Aksentijevich I
The New England journal of medicine.
2014 Mar 6;
370(10).
doi: 10.1056/NEJMoa1307361
PMID: 24552284

The arrival of JAK inhibitors: advancing the treatment of immune and hematologic disorders.

Furumoto Y, Gadina M
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.
2013 Oct;
27(5).
doi: 10.1007/s40259-013-0040-7
PMID: 23743669

Kinase inhibitors in the treatment of immune-mediated disease.

Kontzias A, Laurence A, Gadina M, O'Shea JJ
F1000 medicine reports.
2012;
4().
doi: 10.3410/M4-5
PMID: 22403586

HiJAKing Innate Lymphoid Cells?

Sciumè G, Le MT, Gadina M
Frontiers in immunology.
2017;
8().
doi: 10.3389/fimmu.2017.00438
PMID: 28450869

Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction.

Furumoto Y, Smith CK, Blanco L, Zhao W, Brooks SR, Thacker SG, Abdalrahman Z, Sciumè G, Tsai WL, Trier AM, Nunez L, Mast L, Hoffmann V, Remaley AT, O'Shea JJ, Kaplan MJ, Gadina M
Arthritis & rheumatology (Hoboken, N.J.).
2017 Jan;
69(1).
doi: 10.1002/art.39818
PMID: 27429362

Dense genotyping of immune-related loci implicates host responses to microbial exposure in Behçet's disease susceptibility.

Takeuchi M, Mizuki N, Meguro A, Ombrello MJ, Kirino Y, Satorius C, Le J, Blake M, Erer B, Kawagoe T, Ustek D, Tugal-Tutkun I, Seyahi E, Ozyazgan Y, Sousa I, Davatchi F, Francisco V, Shahram F, Abdollahi BS, Nadji A, Shafiee NM, Ghaderibarmi F, Ohno S, Ueda A, Ishigatsubo Y, Gadina M, Oliveira SA, Gül A, Kastner DL, Remmers EF
Nature genetics.
2017 Mar;
49(3).
doi: 10.1038/ng.3786
PMID: 28166214

Generation and differentiation of induced pluripotent stem cells reveal ankylosing spondylitis risk gene expression in bone progenitors.

Layh-Schmitt G, Lu S, Navid F, Brooks SR, Lazowick E, Davis KM, Montagna C, Gadina M, Colbert RA
Clinical rheumatology.
2017 Jan;
36(1).
doi: 10.1007/s10067-016-3469-5
PMID: 27864696

Biallelic hypomorphic mutations in a linear deubiquitinase define otulipenia, an early-onset autoinflammatory disease.

Zhou Q, Yu X, Demirkaya E, Deuitch N, Stone D, Tsai WL, Kuehn HS, Wang H, Yang D, Park YH, Ombrello AK, Blake M, Romeo T, Remmers EF, Chae JJ, Mullikin JC, Güzel F, Milner JD, Boehm M, Rosenzweig SD, Gadina M, Welch SB, Özen S, Topaloglu R, Abinun M, Kastner DL, Aksentijevich I
Proceedings of the National Academy of Sciences of the United States of America.
2016 Sep 6;
113(36).
doi: 10.1073/pnas.1612594113
PMID: 27559085

Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease.

Zhou Q, Wang H, Schwartz DM, Stoffels M, Park YH, Zhang Y, Yang D, Demirkaya E, Takeuchi M, Tsai WL, Lyons JJ, Yu X, Ouyang C, Chen C, Chin DT, Zaal K, Chandrasekharappa SC, Hanson EP, Yu Z, Mullikin JC, Hasni SA, Wertz IE, Ombrello AK, Stone DL, Hoffmann P, Jones A, Barham BK, Leavis HL, van Royen-Kerkof A, Sibley C, Batu ED, Gül A, Siegel RM, Boehm M, Milner JD, Ozen S, Gadina M, Chae J, Laxer RM, Kastner DL, Aksentijevich I
Nature genetics.
2016 Jan;
48(1).
doi: 10.1038/ng.3459
PMID: 26642243

Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases.

Schwartz DM, Bonelli M, Gadina M, O'Shea JJ
Nature reviews. Rheumatology.
2016 Jan;
12(1).
doi: 10.1038/nrrheum.2015.167
PMID: 26633291

Additive loss-of-function proteasome subunit mutations in CANDLE/PRAAS patients promote type I IFN production.

Brehm A, Liu Y, Sheikh A, Marrero B, Omoyinmi E, Zhou Q, Montealegre G, Biancotto A, Reinhardt A, de Jesus AA, Pelletier M, Tsai WL, Remmers EF, Kardava L, Hill S, Kim H, Lachmann HJ, Megarbane A, Chae JJ, Brady J, Castillo RD, Brown D, Casano AV, Gao L, Chapelle D, Huang Y, Stone D, Chen Y, Sotzny F, Lee CC, Kastner DL, Torrelo A, Zlotogorski A, Moir S, Gadina M, McCoy P, Wesley R, Rother KI, Hildebrand PW, Brogan P, Krüger E, Aksentijevich I, Goldbach-Mansky R
The Journal of clinical investigation.
2016 Feb;
126(2).
doi: 10.1172/JCI86020
PMID: 26829627

Latest News

Research Brief | January 9, 2017

Tofacitinib Shows Potential for Treating Lupus

A drug that effectively treats rheumatoid arthritis (RA) and can improve symptoms in other autoimmune diseases may also control the symptoms associated with systemic lupus erythematosus (SLE or lupus) and potentially slow the disease’s progression.

Contact Us

Ronnie Gladney

IRP Support Staff
9000 Rockville Pike
Bldg 10, Room 10N311
Bethesda MD 20892
Last Updated: May 2020